Barclays’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-135,000
| Closed | -$2.82M | – | 5160 |
|
|
2021
Q1 | $2.82M | Buy |
135,000
+50,000
| +59% | +$1.15M | ﹤0.01% | 1997 |
|
|
2020
Q4 | $1.95M | Buy |
+85,000
| New | +$1.62M | ﹤0.01% | 2253 |
|
|
2020
Q3 | – | Sell |
-95,200
| Closed | -$1.29M | – | 5755 |
|
|
2020
Q2 | $1.29M | Buy |
+95,200
| New | +$1.11M | ﹤0.01% | 2527 |
|
|
2020
Q1 | – | Sell |
-85,900
| Closed | -$2.14M | – | 6623 |
|
|
2019
Q4 | $2.14M | Sell |
85,900
-67,400
| -44% | -$1.37M | ﹤0.01% | 2924 |
|
|
2019
Q3 | $2.61M | Buy |
153,300
+35,300
| +30% | +$643K | ﹤0.01% | 2537 |
|
|
2019
Q2 | $2.69M | Buy |
+118,000
| New | +$3.18M | ﹤0.01% | 2568 |
|
|
2018
Q4 | – | Sell |
-2,700
| Closed | -$78K | – | 7530 |
|
|
2018
Q3 | $78K | Buy |
+2,700
| New | +$81.1K | ﹤0.01% | 5777 |
|
|
2017
Q1 | – | Sell |
-300,000
| Closed | -$3.63M | – | 7084 |
|
|
2016
Q4 | $3.63M | Buy |
+300,000
| New | +$3.88M | ﹤0.01% | 1619 |
|
Barclays's XENT Position: Q2 2022 in Review
Barclays sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 355,531 shares — an estimated $9.96M sold.
Barclays first reported a position in XENT in Q4 2014 and held it in 30 quarters. The position peaked at $12.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Barclays reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Barclays sold 355,531 Intersect ENT, Inc shares in Q2 2022, an estimated $9.96M.
- Barclays first reported a position in Intersect ENT, Inc in Q4 2014 and held it in 30 quarters.
- Barclays's Intersect ENT, Inc position peaked at $12.5M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.